Latest Recruitment News

Hiremii Limited reports a modest 0.4% revenue increase to $7.5 million in Q2 FY25, underpinned by strategic AI platform deployment and expanding Energy Transition sector opportunities.

TrivarX has secured positive feedback from the FDA on its pivotal trial design for MEB-001, an AI-driven algorithm targeting major depressive episode screening via sleep study data. The company is advancing site collaborations to launch a large-scale US trial.

Anatara Lifesciences has been granted a key Australian patent for its GaRP gastrointestinal health product, reinforcing its intellectual property portfolio ahead of pivotal clinical trial results expected in March 2025.

Clarity Pharmaceuticals will present compelling data on its 64Cu-SAR-bisPSMA diagnostic agent at two leading oncology conferences, highlighting earlier and more accurate prostate cancer lesion detection than current standards.

Aura Energy has reported a substantial 49% increase in Ore Reserves at its flagship Tiris Uranium Project, advancing towards a Final Investment Decision in early 2025 while also benefiting from positive regulatory shifts in Sweden.

Dimerix Limited has inked a lucrative licensing agreement with Fuso Pharmaceutical for its kidney disease drug DMX-200 in Japan, while completing recruitment for its pivotal Phase 3 ACTION3 trial.

Paradigm Biopharmaceuticals has secured a $6.3 million R&D Tax Incentive refund, lifting its cash reserves to $31 million and reinforcing its push into Phase 3 osteoarthritis clinical trials.

Tower Limited has appointed CFO Paul Johnston as interim CEO following Blair Turnbull's resignation, with Deputy CFO Angus Shelton stepping in as interim CFO pending regulatory approval.

Mayfield Childcare is nearing the appointment of a new CEO while enacting significant board changes, including the elevation of Lubna Matta to Executive Director and Roseanne Healy to Chair.

Santana Minerals has reported a robust Pre-feasibility Study for its Bendigo-Ophir Gold Project, lifting the after-tax NPV to A$1.2 billion and IRR to 76%, as it progresses detailed engineering and fast-track permitting in New Zealand.

The Calmer Co. International Limited has reported a remarkable surge in sales and cash receipts for the first half of FY25, exceeding the entire FY24 sales. Alongside a strategic CEO transition and factory upgrade, the company is sharpening its focus on profitable growth and cost control.

SelfWealth Limited reported a modest revenue increase for the half-year ended December 2024, yet profits plunged sharply due to higher operating expenses as the company prepares for a potential acquisition by Bell Financial Group.